[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.idisantiago.es\/wp-content\/uploads\/2022\/02\/Grupo-C016-2.jpg” title_text=”Grupo C016″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_toggle title=”Objectives and lines of research” admin_label=”Objetivos y l\u00edneas de investigaci\u00f3n” _builder_version=”4.17.4″ _module_preset=”default” body_font=”|300|||||||” global_colors_info=”{}”]<\/p>\n
Objectives<\/h3>\n
The cardioCHUS research group was established in 2000 under the Cardiology Service of the Santiago de Compostela University Hospital Complex, with the mission of contributing to improving the cardiovascular health of the population. For this, the cardioCHUS group develops an intense research, clinical and translational work, whose objective is to implement new prevention, diagnostic and therapeutic strategies that improve the quality of care and the prognosis of cardiovascular patients. Currently, the cardioCHUS group is accredited as one of the Competitive Reference Groups of the Galician Innovation Agency and is rated as one of the 10 best cardiovascular research groups in Spain since the establishment of the Cardiovascular Area of \u200b\u200bthe Center for Biomedical Research Network, CIBERCV, in 2017.<\/p>\n
Lines of research<\/h3>\n\n- Identification of new diagnostic\/prognostic biomarkers and new therapeutic targets associated with:
– Pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF). REDINSCOR III
– Atrial fibrillation “de novo” in patients with HF: incidence; predictors and relevance. FAISCA Study
– HF patients undergoing cardiac resynchronization therapy (CRT)
– Brugada syndrome
– Cardiac amyloidosis<\/li>\n - Monitoring of cardiac function during treatment with cardiotoxic agents in antineoplastic therapy and identification of cardioprotective strategies, treatment with spironolactone and b-blockers<\/li>\n
- Clinical trials with investigational drugs, new indications in approved drugs and health products, as well as comparative studies on health interventions.<\/li>\n
- Trials with innovative therapies (monoclonal antibodies, iRNA, antisense oligonucleotides, etc.)<\/li>\n
- Evaluation of the clinical impact and the quality of care of new models of patient care management through the inclusion of electronic consultations (e-consultation) in outpatient care programs<\/li>\n<\/ul>\n
[\/et_pb_toggle][et_pb_toggle title=”Research team” admin_label=”Equipo investigador” _builder_version=”4.21.0″ _module_preset=”default” body_font=”|300|||||||” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
– Pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF). REDINSCOR III
– Atrial fibrillation “de novo” in patients with HF: incidence; predictors and relevance. FAISCA Study
– HF patients undergoing cardiac resynchronization therapy (CRT)
– Brugada syndrome
– Cardiac amyloidosis<\/li>\n
[\/et_pb_toggle][et_pb_toggle title=”Research team” admin_label=”Equipo investigador” _builder_version=”4.21.0″ _module_preset=”default” body_font=”|300|||||||” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
![\"Jos\u00e9](\"https:\/\/www.idisantiago.es\/wp-content\/uploads\/2022\/02\/Gonzalez-Juanatey-320x320.jpg\")
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/a>\n\t